low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact: (1) ability to raise capital as risk appetite contracts, (2) partnership deal flow as pharma companies conserve cash, (3) patient enrollment if economic stress affects trial participation. The -$14.5M annual cash burn is fixed regardless of economic conditions. CNS drug demand post-approval is non-cyclical (patients require treatment in all environments).

High sensitivity through valuation mechanics. As a pre-revenue asset, DRUG equity value represents discounted future cash flows 5-10 years forward. Rising risk-free rates (10Y Treasury) increase the discount rate applied to these distant cash flows, compressing present value. Additionally, higher rates reduce speculative capital flows into high-risk biotech, tightening financing conditions. The company's $25M+ cash position benefits marginally from higher interest income, but this is immaterial versus valuation impact. Fed policy shifts can drive 20-40% moves in small-cap biotech indices.

growth/speculative - Attracts biotech-specialized funds, venture crossover investors, and retail momentum traders. The 124% 1-year return and 45% 3-month gain signal momentum-driven interest. Institutional holders likely include healthcare-focused hedge funds (Perceptive, RTW, Boxer) and specialist biotech funds willing to underwrite binary clinical risk. No dividend, negative earnings eliminate value/income investors. High volatility and event-driven catalysts suit traders with options strategies around data readouts. Not appropriate for risk-averse capital.